Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
A 2-year pragmatic open-label trial finds once-weekly semaglutide modestly outperforms physician-chosen alternatives on HbA1c targets, with a year-1 weight advantage that fades by year 2. PICO summary and commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
Once-weekly semaglutide 2.4 mg cut body weight by an estimated 8.3% more than placebo over 44 weeks in Chinese adults with overweight or obesity in the STEP 7 trial. PICO summary and expert commentary.
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.
Post-hoc STEP 6 subgroup analysis of semaglutide versus placebo in 401 Japanese and Korean adults with overweight or obesity, testing whether sex, type 2 diabetes, and other baseline factors modify weight loss. PICO summary and expert commentary.
An exploratory post hoc analysis suggesting tirzepatide improves insulin sensitivity more per unit weight loss than semaglutide in type 2 diabetes. PICO summary and expert commentary.
A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
